Analyst firms · Leerink Partners · AVIR

Leerink Partners AVIR price target and rating history

Atea Pharmaceuticals Inc. (AVIR) · Health Care

Leerink Partners rates Atea Pharmaceuticals Inc. (AVIR) Market Perform with a $9 price target, as of its latest action on Mar 1, 2022. It has published 6 rating actions on AVIR since September 2021, including 0 upgrades and 2 downgrades.

Current rating
Market Perform
Price target
$9
Median target, all firms
Too few
Actions on AVIR
6

Leerink Partners price target on AVIR

$60$35$920222023202420252026
Leerink Partners price target on AVIR, each point a stated target, September 2021 to March 2022.

Every Leerink Partners rating on AVIR

Questions about Leerink Partners and AVIR

What is Leerink Partners's price target for AVIR?
Leerink Partners's latest stated price target for Atea Pharmaceuticals Inc. (AVIR) is $9, from its action on Mar 1, 2022.
What is Leerink Partners's rating on AVIR?
Leerink Partners rates AVIR Market Perform, a neutral rating, as of Mar 1, 2022.
When did Leerink Partners last change its view on AVIR?
On Mar 1, 2022, Leerink Partners cuts its price target to $9 from $10, keeps Market Perform.

More AVIR rating histories

All Leerink Partners ratingsAVIR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.